article thumbnail

Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure

Open Heart

Background Short-term improvements in quality of life (QOL) have been reported in adult congenital heart disease patients with systemic right ventricle (sRV) failure after treatment with sacubitril/valsartan. The TAAQOL was taken at structured outpatient follow-up moments after 6, 12, 24 and 36 months of treatment.

article thumbnail

Research study shows the cost-effectiveness of AI-enhanced heart failure screening

Science Daily - Heart Disease

Earlier research showed that primary care clinicians using AI-ECG tools identified more unknown cases of a weak heart pump, also called low ejection fraction, than without AI. New study findings suggest that this type of screening is also cost-effective in the long term, especially in outpatient settings.

Research 123
article thumbnail

Outpatient care of adults with congenital heart disease in the UK: a qualitative appraisal of the clinician perspective

Open Heart

Objective This study aimed to explore clinicians’ perspectives of ambulatory care in adult congenital heart disease (ACHD). Methods Semistructured interviews were carried out remotely (Zoom) with a range of physicians providing ambulatory care to patients with ACHD across the UK.

article thumbnail

Abstract 4147236: Healing Hearts Mending Minds: Battling Anxiety and Depression in adults with congenital heart disease.

Circulation

Background/Introduction:Adults with congenital heart disease have higher rates of anxiety, depression, and suicide, compared to those without congenital heart disease. 49%, ( n = 44) were either seen in clinic by the psychologists and 22%, (n=20) followed up with an outpatient visit.

article thumbnail

Hackensack Meridian Jersey Shore University Medical Center Providing State-of-the-Art Medtronic APOLLO Clinical Trial Treating Heart Valve Disease

DAIC

The Intrepid TMVR is a heart valve that is designed to help alleviate mitral regurgitation so that blood can flow through the heart in the intended direction,” said Matthew Saybolt , M.D., FACC, principal site investigator and medical director, Structural Heart Disease Program, Jersey Shore University Medical Center. “It

article thumbnail

FDA Commissioner, Host of Cardiovascular Leaders to Offer Keynote Addresses at ACC.24

DAIC

McNamara Keynote Unlocking the Diversity Key in the Pediatric and Adult Congenital Heart Disease Workforce Saturday, April 6, Noon – 1:15 p.m. I ntroducing Isabel-Jones will be Annette Kesewah Ansong, MD , Medical Director, Outpatient Cardiology, Children’s National Hospital (Wash, DC) The 55th Annual Louis F.

article thumbnail

Considerations for Gender?Affirming Hormonal and Surgical Care Among Transgender and Gender Diverse Adolescents and Adults With Congenital Heart Disease

Journal of the American Heart Association

Journal of the American Heart Association, Ahead of Print. BackgroundTransgender and gender diverse (TGD) individuals and long‐term survivors with adult congenital heart disease (ACHD) are both growing populations with specialized needs. Thirty‐three TGD individuals with ACHD were identified, 21 with a history of GAHT/S.